Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00321594
First received: May 2, 2006
Last updated: January 30, 2013
Last verified: December 2012
  Purpose

This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth


Condition Intervention Phase
Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer
Drug: belinostat
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of belinostat in patients with inoperable HCC (Phase I) [ Time Frame: Course 1 ] [ Designated as safety issue: Yes ]
    DLT is defined as any grade 4 hematological toxicity and any grade 3 or 4 non hematological toxicity during cycle 1, excluding alopecia. Specifically, grade 3 nausea, vomiting, or diarrhea that does not respond to therapy is considered dose-limiting. Also, delays in treatment greater than 2 weeks are also dose-limiting. MTD is defined as the dose below which >= 2 of 3 or >= 2 of 6 patients experience DLT. Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.

  • Tumor response in patients with inoperable HCC using belinostat (Phase II) [ Time Frame: Every 2 courses (approximately 6 weeks) ] [ Designated as safety issue: No ]
    Evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. The 95% confidence intervals should be provided.


Enrollment: 61
Study Start Date: May 2006
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (enzyme inhibitor therapy)
Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Drug: belinostat
Given IV
Other Name: PXD101

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD) of PXD101 (belinostat) in patients with unresectable hepatocellular carcinoma (HCC). (Phase I) II. Assess the pharmacokinetic profiles of PXD101 in these patients. (Phase I) III. Assess tumor response in patients treated with this drug. (Phase II)

OUTLINE: This is a multicenter, dose-escalation phase I study followed by a phase II study.

PHASE I: Patients receive belinostat intravenously (IV) over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of belinostat until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

PHASE II: Patients receive belinostat (as in phase I) at the MTD determined in phase I.

After completion of study therapy, patients are followed for up to 8 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed hepatocellular carcinoma that is not amenable to curative resection
  • Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with MRI or spiral CT scan
  • No known brain metastases
  • No clinical ascites or encephalopathy
  • Life expectancy > 12 weeks
  • ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
  • WBC ≥ 3,000/mm³
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 1.7 mg/dL
  • Albumin ≥ 2.8 mg/dL
  • ALT ≤ 5.0 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 6 times ULN
  • Prothrombin time ≤ 4 sec above ULN
  • Creatinine ≤ 1.6 mg/dL
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients use effective contraception
  • No Child's-Pugh's grading Class C hepatic impairment
  • No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PXD101
  • No marked baseline prolongation of QT/QTc interval, including the following:

    • Repeated demonstration of a QTc interval > 500 msec
    • Long QT Syndrome
  • No ongoing or active infection
  • No significant cardiovascular disease, including any of the following:

    • Unstable angina pectoris
    • Uncontrolled hypertension
    • Congestive heart failure related to primary cardiac disease
    • Condition requiring anti-arrhythmic therapy
    • Ischemic or severe valvular heart disease
    • Myocardial infarction within the past 6 months
  • No psychiatric illness or social situation that would preclude study compliance
  • No other uncontrolled illness
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
  • More than 4 weeks since prior radiotherapy and recovered
  • At least 2 weeks since prior valproic acid
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent participation in another investigational study
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy
  • No concurrent use of any of the following:

    • Disopyramide
    • Dofetilide
    • Ibutilide
    • Procainamide
    • Quinidine
    • Sotalol
    • Bepridil
    • Amiodarone
    • Arsenic trioxide
    • Cisapride
    • Calcium channel blockers (e.g., lidoflazine)
    • Clarithromycin
    • Erythromycin
    • Halofantrine
    • Pentamidine
    • Sparfloxacin
    • Domperidone
    • Droperidol
    • Chlorpromazine
    • Haloperidol
    • Mesoridazine
    • Thioridazine
    • Pimozide
    • Methadone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00321594

Locations
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Singapore
Cancer Therapeutics Research Group
Singapore, Singapore, 119074
Sponsors and Collaborators
Investigators
Principal Investigator: Winnie Yeo Chinese University of Hong Kong-Prince of Wales Hospital
  More Information

No publications provided by National Cancer Institute (NCI)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00321594     History of Changes
Obsolete Identifiers: NCT01251445
Other Study ID Numbers: NCI-2009-00141, CTRG-HC06/21/05, N01CM62205, CDR0000463519
Study First Received: May 2, 2006
Last Updated: January 30, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Liver Neoplasms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Adenocarcinoma
Belinostat
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 14, 2014